摘要
目的探究并分析亚硒酸钠联合左旋甲状腺素片治疗桥本甲状腺炎的临床疗效及对TLR7、TLR9水平的影响。方法选取2017年4月至2018年4月在本院治疗的100例桥本甲状腺炎患者,所有患者按照随机数字表法将其分为两组,各50例。对照组采用左旋甲状腺素片治疗,观察组在对照组基础上给予亚硒酸钠治疗。观察并记录两组患者血清TLR7、TLR9水平,治疗效果以及不良反应。结果治疗前,两组患者TLR7、TLR9比较,差异均无统计学意义(均P>0.05);治疗1m、3m,观察组降低程度明显大于对照组,差异均有统计学意义(均P<0.05);观察组治疗总有效率92.0%,高于对照组72.0%,差异有统计学意义(P<0.05);对照组不良反应发生率18.0%,与观察组16.0%比较,差异无统计学意义(P>0.05)。结论亚硒酸钠联合左旋甲状腺素片能有效提高桥本甲状腺炎的临床疗效,改善血清TLR7、TLR9水平,并未发现严重不良反应,值得临床推广。
Objective To explore and analyze the clinical efficacy of sodium selenite combined with levothyroxine tablets in the treatment of Hashimoto's thyroiditis and its effect on TLR7 and TLR9 levels. Methods 100 patients with Hashimoto‘s’ thyroiditis treated at our hospital from April, 2017 to April, 2018 were included in this study. The patients were divided into an observation group and a control group according to random number table, 50 cases for each group. The control group were treated with levothyroxine tablets, while the observation group with levothyroxine tablets and sodium selenite. The curative effect and serum levels of TLR7 and TLR9 were observed and recorded. Results Before the treatment, there were no statistical differences in the TLR7 and TLR9 between the two groups (both P > 0.05). After the treatment for one month and three months, the TLR7 and TLR9 were lower in the observation group than in the control group, with statistical differences (all P< 0.05). The total effective rate was 92.0% in the observation group, and was 72.0% in the control group (P < 0.05). The incidence of adverse reactions was 18.0% in the control group, and was 16.0% in the observation group(P >0.05). Conclusion Sodium selenite combined with levothyroxine tablets for Hashimoto's thyroiditis can effectively improve the clinical efficacy and the serum levels of TLR7 and TLR9, and has no serious adverse reactions, so it is worthy of clinical promotion.
作者
盛晨曦
张淑宏
王宇
Sheng Chenxi;Zhang Shuhong;Wang Yu(Second Department of Endocrinology,Shanxian Central Hospital,Heze 274300,China;Nancheng People’sHealth Care Center,Shanxian,Heze 274300,China)
出处
《国际医药卫生导报》
2019年第14期2356-2358,共3页
International Medicine and Health Guidance News
